Latest Breaking News On - Advisors lp baker - Page 11 : comparemela.com

Bros Advisors Lp Baker Buys 1,888,800 Shares of Neoleukin Therapeutics, Inc (NASDAQ:NLTX) Stock

Bros Advisors Lp Baker Buys 1,888,800 Shares of Neoleukin Therapeutics, Inc (NASDAQ:NLTX) Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Us bancorpNeoleukin therapeutics incWalleye capitalHightower advisorsNeoleukin therapeuticsGet free reportAdvisors lp bakerTower advisorsJane street groupNeoleukin therapeutics daily

Neoleukin Therapeutics, Inc (NASDAQ:NLTX) Director Bros Advisors Lp Baker Purchases 166,942 Shares

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) Director Bros. Advisors Lp Baker purchased 166,942 shares of the stock in a transaction on Thursday, August 17th. The stock was acquired at an average cost of $0.69 per share, for a total transaction of $115,189.98. Following the completion of the acquisition, the director now owns 5,612,949 […]

Securities exchange commissionNeoleukin therapeutics incKestra private wealth servicesShay capitalWalleye capitalVirtu financialNeoleukin therapeuticsGet free reportAdvisors lp bakerExchange commissionPrivate wealth servicesNeoleukin therapeutics dailyNasdaq nltxInsider tradingNsider trades

ACADIA Pharmaceuticals (NASDAQ:ACAD) Rating Reiterated by Oppenheimer

Oppenheimer reissued their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report report published on Thursday, Benzinga reports. They currently have a $25.00 price target on the biopharmaceutical company’s stock. Other analysts have also recently issued research reports about the stock. JMP Securities upped their price objective on […]

United statesJames kiharaPharmaceuticals trading downCm bidwell associates ltdSecurities exchange commissionPharmaceuticals dailyJpmorgan chase coChina universal asset management coPharmaceuticals company profileNisa investment advisorsNemes rush groupPharmaceuticals incCantor fitzgeraldFree reportModerate buyTrading down

ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $38 00 by Analysts at Canaccord Genuity Group

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its target price lowered by Canaccord Genuity Group from $39.00 to $38.00 in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the company. StockNews.com began coverage […]

United statesStephen davisPharmaceuticals stock downAcadia pharmaceuticalsNemes rush groupMorgan stanleyCanaccord genuity groupPharmaceuticals company profileCm bidwell associates ltdNisa investment advisorsPharmaceuticals dailyPharmaceuticals incChina universal asset management coFree reportModerate buyStock down

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $23 00 Price Target at Oppenheimer

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $23 00 Price Target at Oppenheimer
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesStephen davisCm bidwell associates ltdExchange traded conceptsAcadia pharmaceuticalsCredit suisse groupNisa investment advisorsPharmaceuticals stock performancePharmaceuticals dailyPharmaceuticals incChina universal asset management coFree reportSuisse groupModerate buyGet free reportAdvisors lp baker